A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting · Phase 3 · NCT06149286
Conditions: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
At a glance
- Research payments reported, 2025
- $605,384
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 580
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Odronextamab (drug), Lenalidomide (drug), Rituximab (drug)
- Dates
- Started 2023-12-28; completion 2031-04-30
- Results posted
- Not yet
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determ…
From ClinicalTrials.gov, last updated 2026-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $605,384 in research payments for this study in 2025 (68 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John M. Timmerman, MD Hematology & Oncology · Los Angeles, CA
- Chintan C. Gandhi, M.D. Hematology & Oncology · Tamarac, FL
- Varun Mittal, MD Hematology · Indianapolis, IN
- Frederick Lansigan, M.D. Hematology & Oncology · Lebanon, NH
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Thomas Jandl, M.D. Hematology & Oncology · Stony Brook, NY
- Timothy R. Wassenaar, MD Hematology & Oncology · Waukesha, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Resnick Neuropsychiatric Hospital at UCLA, CA $451,076
- Dartmouth Hitchcock Clinic $44,741
- Brcr Medical Center Inc $36,150
- The Research Foundation for The State University of New York $29,488
- Indiana University $25,229
- Clinical Research Alliance Inc $17,200
- Prohealth Care Inc $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.